Expression of the cell surface receptor Fas is frequently lost or decreased during tumor progression in human colon carcinomas. The methylation status of a 583 bp CpG-rich region within the Fas promoter (À575 to +8) containing 28 CpG sites was determined in human colon carcinoma cell lines. In Caco2 (no Fas expression), 82-93% of CpG sites were methylated, whereas none were methylated in GC 3 /c1 (high Fas expression). In RKO (intermediate level of Fas), a single CpG site, located at -548, was 100% methylated. The inhibitor of methylation, 5-aza-2 0 -deoxycytidine (5-azadC), upregulated Fas expression in four of eight cell lines, and sensitized RKO cells to recombinant FasL-induced apoptosis. The p53-binding region in the first intron of the Fas gene was partially methylated in Caco2, and 5-azadC potentiated Ad-wtp53-induced upregulation of Fas expression. Methylation-specific PCR of the first intron detected partial methylation in four out of 10 colon carcinoma tumor samples in vivo. The data suggest that DNA hypermethylation is one mechanism that contributes to the downregulation of Fas expression and subsequent loss of sensitivity to Fas-induced apoptosis in colon carcinoma cells.
Introduction
The cell surface receptor Fas (APO-1; CD95) is a member of the family of death receptors that induce apoptosis in sensitive cells upon binding to their specific death ligands. Fas and its ligand (FasL) are known regulators of apoptosis in cells of the immune system. 1 Analyses of tissues from mice have demonstrated expression of Fas in tissues largely characterized by high rates of cell turnover and apoptotic cell death, including epithelial tissues. 2 Fas is highly expressed in normal human colonic epithelial cells and its expression is progressively decreased during tumor progression from normal epithelium to adenocarcinoma in E50% of the cases. 3, 4 Several reports have demonstrated activation of the Fas signaling pathway in the antitumor activity of 5-fluorouracil (FUra), the most important chemotherapeutic agent used in the therapy of colon carcinomas. [5] [6] [7] [8] We have demonstrated previously that sensitivity to Fas-mediated apoptosis correlated with the level of Fas expressed in human colon carcinoma cell lines. 9 No mutations were detected in the Fas cDNA, and no gross gene rearrangements or frequent allelic loss of the Fas gene have been reported to date. 10 Further, upregulation of Fas expression using the cytokine IFN-g sensitized cells to Fas-mediated and FUra/LV-induced cytotoxicity in a Fas-dependent manner. 6 However, the mechanism of loss of Fas expression and decreased sensitivity to Fas-mediated apoptosis in colon carcinomas remains to be determined. The current study examined whether Fas expression was downregulated by DNA hypermethylation, and whether inhibition of DNA methylation by 5-azadC could upregulate Fas expression and sensitize cells to Fas-mediated apoptosis.
Methylation is the main epigenetic modification in humans, and changes in patterns of DNA methylation play an important role in tumorigenesis. There is increasing evidence that de novo methylation of promoter-associated CpG islands is involved in the transcriptional silencing of several genes and contributes to the alteration of gene expression in cancer. These genes include not only classical tumor suppressor genes involved in cell cycle regulation or DNA repair, but also genes important in apoptosis such as caspase-8 11 and Apaf-1.
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The human Fas gene contains a 650 bp CpG island spanning the 5 0 flanking region of the gene, suggesting that CpG methylation could be responsible for downregulating Fas expression. 13 The first intron, which contains a p53 responsive element, is also a region demonstrating high density of CpG sites. 14 This study determined that DNA methylation contributes to the downregulation of Fas expression in 50% of colon carcinoma cell lines examined. Inhibition of methylation by 5-azadC increased Fas expression, restoring sensitivity to Fas-mediated apoptosis and potentiated p53-induced upregulation of Fas expression.
Results

CpG island methylation
The methylation status of 28 CpG sites in the promoter region of the Fas gene was initially examined in GC 3 /c1, RKO and Caco2 human colon carcinoma cell lines using bisulfite genomic sequencing ( Figure 1 ). Bisulfite modification of genomic DNA converts unmethylated deoxycytidine into uracil (read as thymidine) but methylated deoxycytidine remains unmodified. A 583 bp region within the 5 0 promoter (À575 to +8 nucleotide relative to the transcriptional start site) containing the CpG island was PCR amplified from the bisulfite-treated DNA, and the PCR fragments were cloned and sequenced, thereby allowing identification of the methylation status of each of the 28 specific CpG sites in the Fas gene. In GC 3 /c1 cells with high levels of Fas expression, no CpG sites were methylated in the 10 clones analyzed. In RKO cells with moderate levels of Fas expression, a single CpG site located at position -548 was methylated in all eight clones. In Caco2 cells, which do not express Fas, 14 CpG sites were 100% methylated, at least 23 sites out of 28 were 82% methylated in all seven clones (Figure 1 ).
DNA methylation and Fas expression
To provide evidence for a possible role of DNA methylation in the regulation of Fas expression, cell surface Fas levels were analyzed by flow cytometry both before and after treatment with the demethylating agent 5-azadC (1 mM) for 72 h ( Figure  2a) (Figure 2b ). Both CH-11 (200 ng/ ml) and recombinant human FasL (50 ng/ml) induced a 50% increase in apoptosis in GC 3 /c1 cells following a 72 h exposure. The sensitivity of GC 3 /c1 (expressing high levels of Fas) to Fas-induced apoptosis did not change after treatment with 5-azadC. In contrast, RKO cells were resistant to both CH-11-and FasL-induced apoptosis in the absence of 5-azadC, but were sensitized after 5-azadC treatment in response to CH-11 (25% apoptosis) or FasL (40% apoptosis, Po0.01). Caco2 cells were not sensitive to either CH-11 or FasL and were not sensitized in the presence of 5-azadC.
To confirm that hypermethylation of the CpG site at -548 decreased after 5-azadC treatment, RKO cells were treated with 5-azadC (72 h, 1 mM) and the methylation status of the Fas promoter was analyzed by bisulfite genomic sequencing in both the control and treated samples ( Figure 3 ). In the control sample, the CpG -548 was 71% methylated (five out of seven clones) and only 29% (two out of seven clones) methylated in the treated sample. Data suggest that demethylation of this CpG can have a role in the 5-azadCinduced upregulation of Fas in this cell line.
Influence of wtp53
Transcriptional regulation of Fas by wtp53 has been reported in these cell lines. 15 We therefore examined whether hypermethylation of the Fas gene would affect the p53-dependent transcriptional activation of Fas expression. A putative p53 enhancer region exists in the first intron of the Fas gene, 14 and contains 23 CpG sites. We therefore determined the methylation status of the p53 enhancer region by methylation-sensitive PCR (Figure 4a ). There was no detectable methylation of the enhancer region in GC 3 
Effects of 5-azadC on transcription
To determine whether 5-azadC increased Fas expression at the transcriptional level, levels of Fas mRNA were analyzed in RKO and Caco2 cells and in six additional colon carcinoma cell lines before and after treatment with 5-azadC (1 mM) for 72 h ( Figure 6 ). 
DNA methylation and Fas expression in vivo
To explore DNA hypermethylation and Fas expression in primary colon carcinoma samples in vivo, paraffin-embedded archived tumor material derived from 10 independent cases were analyzed. Immunohistochemical staining of tissue sections revealed strong membrane expression of Fas in normal colon epithelium and absent or very low expression in colon carcinoma cells in all cases (Figures 7 and 8 ). Tissue sections from the same paraffin blocks were also used to extract genomic DNA, which was subsequently bisulfite treated. Methylation-specific PCR of the p53 enhancer region detected the presence of unmethylated DNA in all tumor samples. In four out of 10 tumor samples, methylation was detected, the signal being strong in tumors #8 and #9 ( Figure  8 ). These results indicate that methylation of the Fas enhancer region occurs in vivo and may contribute to the downregulation of Fas expression in a subset of colon carcinomas.
Discussion
This report demonstrates correlation between suppressed Fas expression and promoter hypermethylation in human colon carcinoma cell lines. We examined 583 bp of the approximately 650 bp GC-rich 5 0 regulatory region of the Fas gene and determined the methylation status of the 28 CpG sites in this region. The results provide evidence that DNA hypermethylation is one mechanism by which Fas expression can be downregulated in colon carcinoma cells. Consistent with this notion, inhibition of methylation with 5- Our study also indicates that there are additional mechanisms responsible for the downregulation of Fas in certain cell lines. For example, 5-azadC did not upregulate Fas expression in HT29, VRC 5 /c1 or HCT116 cells, although these cell lines express intermediate levels of Fas and are relatively resistant to Fas-mediated apoptosis. 9 The promoter region of Fas has binding sites for several transcription factors including p53, c-myb, NF-kB, Sp-1 and IFN-g response elements such as GAS. 13 P53 and IFN-g are known regulators of Fas expression. P53 is inactivated by mutation or allelic loss in 75% of colorectal cancers, and hence may contribute to decreased Fas expression in this tumor type. Our results show that hypermethylation of the Fas gene inhibited the upregulation of Fas by wtp53; hence DNA methylation can suppress Fas expression despite the presence of a wtp53 gene.
One CpG site only (position À548) was methylated in RKO cells, and this site was frequently methylated in other cell lines of various origins (data not shown). In RKO, 5-azadC upregulated Fas expression several fold and sensitized the cells to FasL-induced apoptosis. Previously, Butler et al. 16 used methylation-sensitive restriction enzymes and Southern blotting to evaluate the methylation status of 9 CpG sites in the Fas promoter. These were determined to be unmethylated in Figure 8 Methylation analysis of the Fas enhancer region in colon carcinoma specimens. Methylation status of the Fas enhancer region was analyzed using methylation specific PCR in 10 specimens of colon carcinoma. Lane M: amplified product with primers recognizing the methylated Fas enhancer sequence. Lane U: amplified product with primers recognizing unmethylated Fas enhancer sequence. The results of immunohistochemical studies for Fas expression were assessed by scoring the intensity of immunoreactivity relative to control staining using a scale: 'À', negative; '+', weak; '++++', strong samples from colorectal carcinomas and adenomas, suggesting that DNA methylation could not account for the frequent loss of expression of the Fas gene in colorectal carcinomas. However, a considerable area of the Fas promoter was not investigated, including the CpG site -548. In addition, a higher density region of CpGs exists in the enhancer region of the first intron, which has not been analyzed previously. Here, we demonstrated that partial methylation of this region occurs in a subset of colon carcinomas.
The antitumor activity of FUra has a Fas-dependent component in colon carcinoma cell lines 6 and other cell types, 8 and is influenced by the level of Fas expressed. Upregulation of Fas by the cytokine IFN-g sensitized colon carcinoma cells to FUra/LV. 6 Our results suggest that inhibitors of methylation also have the potential to upregulate Fas expression independent of the p53 status in colon carcinomas and sensitize the cells to cytotoxic agents, in particular FUra/LV, that utilize the Fas signaling pathway to induce apoptosis and cytotoxicity.
Materials and Methods
Cell lines
The HT29, HCT8 and HCT116 human colon carcinoma cell lines were obtained from ATCC. GC 3 /c1 and VRC 5 /c1 were established as previously reported, 9 and RKO was obtained from Dr. Michael Kastan, St. Jude Children's Research Hospital. Cells were maintained in the presence of folate-free RPMI 1640 medium containing 10% dFBS and 80 nM (6RS)5-methyltetrahydrofolate.
Tissue samples
Ten colon carcinoma tissue samples were obtained from the tissue bank of the Ist Institute of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary. The material had been fixed in buffered formalin and embedded into paraffin.
Genomic sequencing of bisulfite-modified DNA
The selected 583 bp region extending between bp À575 and +8 was PCR amplified from bisulfite-converted genomic DNA extracted from GC 3 /c1, RKO, Caco2 colon carcinoma cell lines and RKO cells treated with 5-azadC (72 h; 1 mM). 17 The following primers were used: 5 0 -GGTTTTTGTATTTAGGTAGGATTTTTG (F) and 5 0 -CCCAACATAAT-TATTAAACAATCCTC (R), corresponding to nucleotides À575 to À549 and +8 to À18, respectively. The PCR product was ligated into the pCR 2.1-TOPO vector and transformed into Top 10F 0 cells using the TOPO TA Cloning kit (Invitrogen, Carlsbad, CA, USA). Clones containing the correct insert were identified by EcoR1 restriction enzyme digestion. Plasmid DNAs were isolated from multiple clones from each colon carcinoma cell line (Qiagen, Chatsworth, CA, USA). DNA sequencing was performed by an automated ABI Prism Big Dye Terminator Cycle Sequencing System (Hartwell Center for Bioinformatics & Biotechnology, St. Jude Children's Research Hospital). The known genomic DNA sequence was compared to the sequence derived from the bisulfite-modified DNA for each clone, and the methylation status of each CpG was determined. In bisulfite-modified DNA, unmethylated cytosine appeared as thymidine, whereas methylated cytosine remained unconverted. The percentage of methylated CpG at each site was calculated from all the PCR clones analyzed from each sample.
Methylation-specific PCR (MSP)
Methylation-specific PCR was performed according to published procedures. 18 Bisulfite-treated genomic DNA isolated from colon carcinoma cell lines GC 3 /C1, RKO and Caco2 was analyzed. In the case of Caco2, DNA from cells previously treated with 5-azadC (1 mM) for 72 h was also analyzed. Genomic DNA was also extracted from paraffinembedded blocks of colon carcinoma specimens using the EX-WAX DNA extraction kit (Intergen) according to the instruction of the vendor. DNA was further purified (Wizard DNA clean-up kit, Promega) and subsequently bisulfite modified using the CpGenome DNA modification kit (Intergen). MSP primer sequences were designed that specifically recognize sequences containing either methylated (CpG) or unmethylated (TpG) sites in the enhancer region of the first intron of the Fas gene. MSP reactions were performed on bisulfite-converted DNA. The following primers were used to discriminate between top-strand methylated and unmethylated CpGs:
Methylated-F:
0 -CACCCACACCAAAACAAACCTTTAAC PCR amplification of the selected region (+630 to +825) in the first intron of the Fas gene to yield 184 and 187 bp products with the methylated and unmethylated primer sets, respectively, was performed under the following conditions: initial denaturation at 941, 3 min; 40 cycles at 941, 1 min; 641, 1 min; 721, 2 min; and a final extension of 721, 4 min. The PCR products (15 ml) were resolved on 2% agarose gels, stained with ethidium bromide and visualized by UV illumination.
RT-PCR analysis of Fas mRNA expression
Colon carcinoma cell lines were cultured in the presence or absence of 1 mM 5-azadC for 72 h in T75 flasks (Falcon), subsequently harvested and subjected to RNA extraction. Total RNA was isolated using the RNAqueous kit (Ambion, Austin, TX, USA). RNA (2 mg) was reverse transcribed using cDNA Cycle Kit (Invitrogen, Carlsbad, CA, USA). Amplification of cDNA was performed using primers specific for Fas and bactin (internal control). Primers specific for Fas receptor cDNA amplification were: (F) 5 0 -GACCCAGAATACCAAGTGCAGATGTA (R) 5 0 -CTGTTTCAGGATTTAAGGTTGGAGATT The primer pair specific for b-actin cDNA was:
0 -CTCCTTAATGTCACGCACGATTTC PCR amplification for Fas and b-actin mRNA was performed under the following conditions to yield 289 and 540 bp products, respectively: initial denaturation at 941, 3 min; 25 cycles at 941, 1 min; 601, 2 min,; 721, 2 min; and a final extension of 721, 4 min. The PCR products were resolved on 1.2% agarose gel, stained with ethidium bromide and visualized by UV illumination.
Apoptosis assays
GC 3 /c1, RKO and Caco2 cells were plated at a density of 200 000 cells/ well in six-well plates. After overnight attachment, cells were cultured for 48 h in the presence or absence of 1 mM 5-azadC. Cells, both previously treated or untreated with 5-azadC, were further treated for 24 h with antiFas MoAb CH-11 (200 ng/ml; MBL International Corp.) or recombinant FasL (50 ng/ml; Alexis) and M2 anti-Flag mAB (1 mg/ml; Sigma). Both the floating cells and attached cells were pooled after trypsinization, fixed in 70% ethanol, and stored at -201C prior to the analysis. Apoptotic cells were detected as a sub-G1 fraction after propidium iodide staining and analysis using a Becton Dickinson FACScan. 19, 20 Expression of cell surface Fas GC 3 /c1, RKO and Caco2 cells were plated at a density of 200 000 cells/well in six-well plates. After overnight attachment, cells were cultured for 72 h in the presence or absence of 5-azadC (1 mM). Cell surface Fas expression was determined by flow cytometry using standard procedures. Throughout the whole study, the same lot (M044107) of phycoerythrin (PE)-labeled anti-Fas mAB (clone DX2; Pharmingen) was used. At each measurement, PE staining was calibrated using Quantibright (Becton Dickinson) beads. Nonviable cells were excluded using 7-aminoactinomycin D (7-AAD) staining. The mean fluorescence intensity values were converted to the number of PE molecules/cell using Quantiquest software. Data were analyzed using the Student's t-test.
Adenoviral delivery of wtp53
Caco2 cells were plated as described earlier, and transduced either with a replication-incompetent wtp53 expressing adenoviral vector (Ad-wtp53; Genetic Therapy Inc.) at multiplicities of infection (moi) of 10, 30 and 100, or with an adenoviral vector control containing the basic vector backbone sequences (Ad-VC; moi 100). Cells were transduced with the adenoviral vectors either alone or in combination with 5-azadC (1 mM) for 72 h. Cells were subsequently harvested, and cell surface Fas expression determined by flow cytometric analysis as described. In order to asses Fas sensitivity, Caco2 cells were transduced with Ad-VC (moi 100) or Ad-wtp53 (moi 100) alone or in combination with 5-azadC (1 mM) for 48 h and subsequently incubated with or without CH-11 (200 ng/ml) for an additional 24 h in the presence or absence of cycloheximide (Sigma) 10 mM. Apoptosis was measured as described.
Expression of Fas in vivo
Sections from paraffin-embedded blocks of normal colon epithelium and 10 colon carcinomas were labeled with anti-Fas antibody (Dako, clone: APO-1, # M3554) in 1 : 5 dilution after pronase digestion. Subsequently, peroxidase-labeled goat anti-mouse secondary antibody (Dako) was used for detection of APO-1 and developed using diaminobenzidine tetrahydrochloride (Sigma) following standard procedure. To assess morphology, hematoxylin stain was applied.
